The Fort Worth Press - Inspire Veterinary Partners Reports Second Quarter 2025 Financial Results

USD -
AED 3.672504
AFN 64.503991
ALL 81.046102
AMD 360.780113
ANG 1.789785
AOA 917.000367
ARS 1523.143125
AUD 1.433486
AWG 1.8025
AZN 1.70397
BAM 1.745704
BBD 2.012675
BDT 123.586379
BGN 1.747831
BHD 0.377114
BIF 2995.403222
BMD 1
BND 1.277279
BOB 11.766859
BRL 4.965204
BSD 0.999331
BTN 94.818583
BWP 13.766234
BYN 2.934172
BYR 19600
BZD 2.009729
CAD 1.40025
CDF 2316.000362
CHF 0.825078
CLF 0.025212
CLP 986.459589
CNY 6.67805
CNH 6.670604
COP 3171.419646
CRC 456.018209
CUC 1
CUP 23.982684
CVE 98.420137
CZK 21.719504
DJF 177.944392
DKK 6.67165
DOP 61.293346
DZD 134.335699
EGP 55.079216
ERN 15
ETB 162.538225
EUR 0.89267
FJD 2.237204
FKP 0.74764
GBP 0.747692
GEL 2.590391
GGP 0.74764
GHS 11.586558
GIP 0.74764
GMD 74.000355
GNF 8843.664926
GTQ 7.638684
GYD 209.291739
HKD 7.84235
HNL 26.828223
HRK 6.728204
HTG 130.968001
HUF 327.370388
IDR 18093.85
ILS 3.10555
IMP 0.74764
INR 94.945504
IQD 1514.883742
IRR 1832375.000352
ISK 121.780386
JEP 0.74764
JMD 158.593297
JOD 0.70904
JPY 156.860385
KES 129.754095
KGS 87.448604
KHR 4082.652742
KMF 439.503794
KPW 899.999961
KRW 1323.525039
KWD 0.31069
KYD 0.832775
KZT 453.715357
LAK 22486.722899
LBP 89486.053465
LKR 331.81595
LRD 170.375329
LSL 16.556076
LTL 2.95274
LVL 0.60489
LYD 6.399786
MAD 9.815504
MDL 18.037221
MGA 4519.123488
MKD 54.987281
MMK 2100.187629
MNT 3599.924651
MOP 8.073191
MRU 39.936627
MUR 47.160378
MVR 15.460378
MWK 1732.762083
MXN 18.668404
MYR 4.085304
MZN 63.903729
NAD 16.556076
NGN 1332.060377
NIO 36.774222
NOK 9.35739
NPR 151.709734
NZD 1.750854
OMR 0.38297
PAB 0.999241
PEN 3.431874
PGK 4.475387
PHP 63.618038
PKR 276.527424
PLN 3.92999
PYG 5779.443924
QAR 3.642612
RON 4.779804
RSD 104.87794
RUB 80.331771
RWF 1476.413621
SAR 3.753249
SBD 8.07458
SCR 13.982238
SDG 601.503676
SEK 9.931804
SGD 1.276904
SHP 0.7473
SLE 22.950371
SLL 20969.504398
SOS 571.07154
SRD 37.628038
STD 20697.981008
STN 21.868166
SVC 8.743696
SYP 13001.999685
SZL 16.555541
THB 33.770369
TJS 9.208462
TMT 3.51
TND 2.983978
TOP 2.40776
TRY 49.703804
TTD 6.789842
TWD 32.585804
TZS 2645.601821
UAH 45.239791
UGX 4402.195742
UYU 40.076762
UZS 11958.762887
VES 879.788904
VND 25842.5
VUV 119.07444
WST 2.767685
XAF 585.553409
XAG 0.018551
XAU 0.000250266221
XCD 2.70255
XCG 1.800955
XDR 0.707052
XOF 585.553409
XPF 106.448878
YER 236.103589
ZAR 16.57373
ZMK 9001.203584
ZMW 20.091043
ZWL 321.999592
SSP 5745.690365
MXV 2.106972
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Inspire Veterinary Partners Reports Second Quarter 2025 Financial Results
Inspire Veterinary Partners Reports Second Quarter 2025 Financial Results

Inspire Veterinary Partners Reports Second Quarter 2025 Financial Results

Comparable clinic revenues increase 5.7% vs prior year period

Net losses decrease 10% vs. prior year period

Text size:

VIRGINIA BEACH, VA / ACCESS Newswire / August 14, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) ("Inspire" or the "Company"), an owner and provider of pet health care services throughout the U.S., today reported financial results for the second quarter ended June 30, 2025.

Second Quarter 2025 Financial Highlights Compared to Prior Periods

  • Total revenue of approximately $4.3 million, a sequential increase of 20% from Q1 2025 and a decrease of 2% from the prior year period. The decrease in revenue is attributed to the exclusion of the Hawaii clinic (KVC) from 2025 results

  • Services revenue of approximately $3.2 million, a sequential increase of 17% from Q1 2025 and a decrease of 1% from the prior year period

  • Product revenue of $1.1 million, a sequential increase of 21% from Q1 2025 and a decrease of 7% from the prior year period

  • Comparable clinic revenues increased 5.7% from the prior year period

  • Total operating expenses of $6.2 million, an increase of 5% from the prior year period

  • Net loss of $3.0 million, a decrease of $0.4 million from the prior year period

  • Entered an exclusive, non-binding Letter of Intent to acquire 100% ownership interest in one animal hospital located in New Jersey. Once completed, the acquisition could potentially add up to approximately $2.0 million in (unaudited) revenue

  • Entered into a securities purchase agreement for the issuance and sale of securities for up to $10M under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share

  • Announced the launch of a company-wide incentive and recognition program, which provides vital new engagement tools and offers new avenues to wealth for all employees across their clinic network

  • Integrated a new artificial intelligence (AI) platform in partnership with leading software provider Covetrus into the Company's medical software. The Company believes this is the only AI platform being offered among publicly traded veterinary clinic networks

  • Acquired 100% ownership interest in one animal hospital located in central Florida (DeBary). The acquisition is expected to add up to approximately $1.8 million in (unaudited) revenue, and brings the Company's Florida holdings up to 5 clinics

  • For the second quarter of 2025, total revenue was approximately $4.3 million, a decrease of 2% from the prior year period but an increase of 20% from Q1 2025. Comparable clinic revenues increased 5.7% from the prior year period.

Second Quarter 2025 Operational Highlights

  • Entered an exclusive, non-binding Letter of Intent to acquire 100% ownership interest in one animal hospital located in New Jersey. Once completed, the acquisition could potentially add up to approximately $2.0 million in (unaudited) revenue

  • Entered into a securities purchase agreement for the issuance and sale of securities for up to $10M under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share

  • Announced the launch of a company-wide incentive and recognition program, which provides vital new engagement tools and offers new avenues to wealth for all employees across their clinic network

  • Integrated a new artificial intelligence (AI) platform in partnership with leading software provider Covetrus into the Company's medical software. The Company believes this is the only AI platform being offered among publicly traded veterinary clinic networks

  • Acquired 100% ownership interest in one animal hospital located in central Florida (DeBary). The acquisition is expected to add up to approximately $1.8 million in (unaudited) revenue, and brings the Company's Florida holdings up to 5 clinics

Executive Commentary

"During the second quarter of 2025, we started to see the rewards of our new initiatives, processes, and hard work over the past 18 months with sequential revenue growth of 20% and year over year organic growth of 5.7%.," said Kimball Carr, Inspire 's Chairman, President and Chief Executive Officer. "We also grew our portfolio of clinics to 14 with the recently announced acquisition in Florida while significantly improving our liquidity and capital structure with the recently announced preferred stock transaction. I believe this quarter will mark the turning point for our business model and that our top line growth will accelerate going forward.

Second Quarter 2025 Financial Overview

All comparisons are made relative to the same period in 2024 unless otherwise stated.

  • For the second quarter of 2025, total revenue was approximately $4.3 million, a decrease of 2% from the prior year period but an increase of 20% from Q1 2025. Comparable clinic revenues increased 5.7% from the prior year period.

  • Service revenue for the second quarter of 2025 decreased $25,000 or 1%, to $3.2 million. The decrease in service revenue is mainly attributed to the exclusion of KVC from 2025 results and reduced practitioner capacity. These decreases were partially offset by the acquisition of the DeBary animal clinic during Q2 2025.

  • Product revenue for the second quarter 2025 decreased $82,000, or 7%, to $1.1 million. The overall decrease was a result of customers purchasing less products per visit and the exclusion of KVC from 2025 results partially offset by the acquisition of the DeBary animal clinic during Q2 2025.

  • Total operating expenses increased $285,000 or 5%. The increase is primarily due to increased costs of consulting agreements relating to customer outreach and public company costs.

  • Net loss for the first quarter of 2025 decreased $352,000, or 10%, to $3.0 million. The decline in net loss is primarily attributable to the reduction of interest expense and the exclusion of the operating expenses associated with KVC.

Balance Sheet

As of June 30, 2025, the Company had cash and cash equivalents of approximately $0.2 million.

About Inspire Veterinary Partners, Inc.

Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care.

For more information, please visit: www.inspirevet.com.

Connect with Inspire Veterinary Partners, Inc.

Facebook

https://www.facebook.com/InspireVeterinaryPartners/

LinkedIn

https://www.linkedin.com/company/inspire-veterinary-partners/

Forward-Looking Statements

This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding management's expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption "Risk Factors" in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Investors
CoreIR
516-386-0430

General Inquiries
Morgan Wood
[email protected]

Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Balance Sheet

Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Statements of Operation

Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Statements of Cash Flows

SOURCE: INSPIRE VETERINARY PARTNERS, INC.



View the original press release on ACCESS Newswire

J.P.Cortez--TFWP